EIC Accelerator Picks RheaVita's Continuous Freeze-Drying

16 November 20262,183 words11 min

Freeze-drying is how the drug industry keeps fragile biologics stable: vials are loaded into a large chamber, frozen and then dried under vacuum in a batch cycle that, in the words of RheaVita's chief executive Thomas De Beer, "takes several days". RheaVita, a Ghent University spin-off, replaces the chamber with a line that handles one vial at a time. On 16 November 2026 the European Innovation Council named it among the companies selected for its Accelerator.

The project, RheaLyo GMP-Flex, described in the EIC's selection list as "Revolutionizing Freeze-Drying for Biopharmaceuticals", was evaluated at the 8 July 2026 cut-off and recommended for blended finance, a grant combined with a possible EIC Fund equity investment. The list gives no amount, and it states that selection "does not constitute a formal commitment for funding". The EIC expects grant agreements within three months of the announcement, so no project is yet public in CORDIS. This article sets out what the company promises and what can already be checked.

35 of 453Companies selected from full applications in the round
€1.61MNet loss in 2025, per the filed accounts
4.4 FTEStaff in the latest filed accounts

Company file

Legal entity
RheaVita BV, enterprise number 0695.884.829, a Belgian private limited company since May 2020
Incorporated
14 May 2018, Ghent
Headquarters
Poortakkerstraat 9B-9C, 9051 Ghent, since October 2023
Leadership
Thomas De Beer, co-founder and CEO; Patrick Baeyens, CFO; Joris Lammens, CTO; co-founder Jos Corver is listed as an advisor
Investors
Novalis Biotech Acceleration and PMV (Series A, 2021); IMA Life (strategic investment, 2024)
Products
RheaLyo Mono and RheaLyo Multi for R&D; RheaLyo GMP-Flex lines for production
EIC project
RheaLyo GMP-Flex, 8 July 2026 cut-off, blended finance, no CORDIS record yet

Spinning the vial instead of filling the chamber

The method is called spin freezing. In an interview with The Medicine Maker published on 30 July 2024, De Beer explained that vials are rotated rapidly along their axis while cold gas freezes the liquid into a thin layer on the vial wall, after which each vial is dried under individual control. On a single-vial R&D unit, he said, the process "can be done quickly, between one and two hours". The company's RheaLyo Mono page claims "Over 40x Faster Freeze-Drying" than batch processing, without stating an absolute cycle time or the formulation behind the figure.

The production version is the subject of the EIC project. The GMP-Flex page calls it "the only commercial GMP-compliant continuous freeze-drying system", with vials handled robotically inside an isolator, and gives a yearly capacity range "from about 100,000 vials up to 2 million vials", depending on the formulation, freezing speed and target moisture. The page names no installed GMP-Flex line and invites visitors to see a demo machine. The exclusivity claim is the company's own; no independent market survey confirming it was found in sources reviewed on 16 November 2026.

The step from lab unit to production line has one peer-reviewed data point. A paper in the International Journal of Pharmaceutics (published online 9 June 2026), written by RheaVita and Bayer authors, transferred a PEGylated peptide process from the RheaLyo Mono to "a GMP-compatible prototype line (GMP-Flex)" with identical settings. It reports matching product temperature profiles, intact cakes, monomer levels close to 100% and residual moisture within the 0.3-0.6% target, with no drift over the production run. The paper describes a prototype, not a customer installation.

The method has a patent base. US patent 10,809,003, "Method and apparatus and container for freeze-drying", lists De Beer and Jozef Corver as inventors and RheaVita as assignee, with a priority date of 16 August 2016 and a grant date of 20 October 2020.

The record

Fourteen years from a process idea to an EIC selection

The concept dates from 2012 by the company's account; the company was incorporated in 2018 and was selected at the 8 July 2026 cut-off for its GMP-Flex production line.

  1. 2012ConceptJos Corver and Thomas De Beer meet and the process concept originates, per the company
  2. Aug 2016Patent priorityPriority date of US 10,809,003, granted in October 2020 for a freeze-drying method, apparatus and container
  3. May 2018IncorporatedRheaVita registered in Ghent on 14 May 2018 after a first prototype built with Ghent University's support
  4. Jun 2021Series ANovalis Biotech Acceleration and PMV co-lead a round to build a first GMP continuous freeze-drying line€2.5M
  5. Jul 2023EU project and lab partnerBAXERNA 2.0 starts with €180,000 for RheaVita; Coriolis Pharma adds RheaVita's single vial unit to its services
  6. Nov 2024IMA Life investsStrategic investment by IMA Life, part of IMA Group, amount not disclosed
  7. May 2025New boardIMA Life's managing director Michele Arduini joins the board, per the KBO
  8. Jun 2026Scale-out paperPeer-reviewed paper by RheaVita and Bayer authors reports a matched transfer from the lab unit to a GMP-compatible prototype line
  9. Jul 2026Cut-offRheaLyo GMP-Flex is evaluated at the 8 July 2026 cut-off; Thermo Fisher and Astellas results are posted by CPHI
  10. Oct 2026Gates grantFive-month grant for continuous lyophilisation of RNA vaccines$318,927
  11. Nov 2026SelectedOne of 35 companies the EIC selects, recommended for blended finance

RheaVita, About page; KBO; BioSpace, 2 June 2021; IMA Group, 18 November 2024; International Journal of Pharmaceutics, 2026; CORDIS, BAXERNA 2.0; CEPI, 11 March 2024; Gates Foundation committed grants; EIC, 16 November 2026.

Who is testing it

The laboratory unit has named users, all of them in development work, per the sources. Coriolis Pharma, a formulation development service provider, announced on 28 July 2023 that it would offer RheaVita's single vial unit to its clients alongside other lyophilisation methods. RheaVita's news page says Patheon, part of Thermo Fisher Scientific, is installing a RheaLyo Mono at its Monza site in Italy, without giving a date.

Two results surfaced in July 2026. CPHI Online posted on 29 July 2026 a study by Thermo Fisher's formulation laboratory in Monza that compared RheaVita's technology with a conventional freeze-dryer on "a challenging formulation", and on the same date an Astellas feasibility study using the RheaLyo Mono, which reported that foreign particles in placebo samples were "easily detected by visual inspection". The Thermo Fisher poster, co-authored by two RheaVita staff, reports a small-molecule formulation with a 7-day conventional cycle finished in 3 hours 30 minutes on RheaVita's dryer ("~98% reduction"), residual moisture below 2% on both, and impurities of 2.11% against 2.65%; it lists "scale-up on the GMP production line, in collaboration with RheaVita" as ongoing. The Astellas poster says processing time per vial was "significantly reduced" in lab-scale work; RheaVita's references page puts that at 97%. An earlier 2023 Ghent University and GSK poster reported 3 hours against 47 hours for batch freeze-drying of a live attenuated viral vaccine. These are conference posters, not peer-reviewed papers. A webinar held with Thermo Fisher on 9 September 2026 was announced with cycle times cut "from days to hours without compromising critical quality attributes", without numbers on the listing.

The vaccine angle

Spin freezing has drawn public-health money as well as industry interest. CEPI announced on 11 March 2024 that Ghent University would receive up to US$1.9 million to test spin-frozen mRNA vaccines against an H2N2 influenza strain, stored at 2 to 8°C, describing the technique as "pioneered by RheaVita". The Gates Foundation lists a grant of $318,927 to RheaVita BV, committed in October 2026 for five months, to evaluate continuous lyophilisation for RNA vaccine manufacturing with low- and middle-income countries in mind. In CORDIS, RheaVita appears as a participant with €180,000 of EU funding in BAXERNA 2.0, a Horizon Europe project on bacterial mRNA vaccines coordinated by VIB and running from 1 July 2023 to 30 June 2028.

Investors and the filed accounts

RheaVita announced on 2 June 2021 a €2.5 million Series A co-led by Novalis Biotech Acceleration and Participatie Maatschappij Vlaanderen (PMV), to "build first GMP compliant biopharmaceutical continuous, controlled, freeze-drying production line". On 18 November 2024 IMA Group announced a strategic partnership in which IMA Life, which RheaVita describes as "a global provider of advanced, aseptic pharmaceutical process and production solutions", made a financial investment in RheaVita; no amount or stake was disclosed. The Crossroads Bank for Enterprises (KBO) records Michele Arduini, whom the IMA announcement names as managing director of IMA Life, as a director since 23 May 2025.

The same register lists four corporate directors appointed in 2025 and 2026. Busibee, which reads the Belgian registers, identifies them as PMV, Qbic Venture Partners III, De Beer's consulting company and Novalis II General Partner. Sources reviewed on 16 November 2026 show no announcement by RheaVita or Qbic of a Qbic investment.

The accounts

Annual losses passed €1.6M in 2024 and 2025

Net losses from the filed accounts, shown as positive values. The first bar covers the extended first financial year from May 2018 to December 2019.

Filed annual accounts as shown by Companyweb (2022 to 2025) and Busibee (2018 to 2021). Values in € millions.

The accounts show a company still spending ahead of revenue. According to Companyweb, turnover was €672,227 in 2024 and €322,343 in 2025, while the net loss was €1,743,146 and €1,607,554. Equity nevertheless rose from €4,252,359 to €6,934,822 in 2025, and the Belgian Official Gazette lists a share capital publication on 10 June 2025; the size of any capital increase is not stated in the sources reviewed. Cash at the end of 2025 was €2,688,565, per Busibee.

The balance sheet

Equity rose to €6.93M in 2025 despite the loss

Equity grew by €2.68M in 2025 while the year's loss was €1.61M; the Belgian Official Gazette lists a share capital publication on 10 June 2025, without an amount in the sources reviewed. Debts peaked at €3.04M in 2023.

Filed annual accounts as shown by Companyweb (2022 to 2025) and Busibee (2020 and 2021). Values in € millions.

Headcount is reported in two ways. The filed accounts give 4.4 full-time equivalents for 2025, up from 3.7 in 2022, while the company's team page lists ten people, including advisors and department leads. The two figures measure different things and are not reconciled in any public source.

The round and the policy case

The EIC's announcement of 16 November 2026 reports 453 full applications, 88 interviews and 35 selected companies from 17 countries, with proposed grant funding of €84 million in total and 32 of the 35 to be assessed for EIC Fund equity of up to €10 million each. Whether RheaVita is among the 32 is not stated. RheaVita's own news page did not mention the selection when read on 16 November 2026.

The competition

One of 35 companies selected from 453 full applications

The May to July 2026 evaluation took 453 full applications to 88 interviews and 35 selections. Selection is not a funding commitment until the grant is prepared.

EIC, The European Innovation Council selects 35 deep tech companies for its Accelerator support, 16 November 2026.

The European interest is in manufacturing capacity for injectable medicines and vaccines. The Commission's health emergency authority runs EUFab, a network of vaccine makers that keeps "ever-warm" production capacity so that Europe can "rapidly scale up vaccine production in response to public health emergencies", in the words of its 3 February 2025 update. CEPI's project tests whether spin-frozen mRNA vaccines hold up when stored at 2 to 8°C rather than frozen. RheaVita is not named in any EUFab document found on 16 November 2026.

What can already be checked

  1. Working continuous freeze-drying for R&DPublicRheaLyo Mono used by Coriolis Pharma since 2023 and evaluated by Thermo Fisher and Astellas, per CPHI, 29 July 2026.
  2. GMP production line, the 2021 Series A goalPrototype testedGMP-Flex is marketed with a demo machine, and a 2026 peer-reviewed paper by RheaVita and Bayer authors reports a matched scale-out to a GMP-compatible prototype; no installed customer line is named.
  3. Speed gain over batch freeze-dryingLab dataConference posters report 7 days cut to 3.5 hours (Thermo Fisher) and 47 hours to 3 hours (GSK) at lab scale; the "40x faster" product claim is the company's own, and no production-scale cycle data are public.
  4. EIC project RheaLyo GMP-FlexToo earlySelected on 16 November 2026; grant agreement expected within three months, no CORDIS record yet.

What the company says

The only commercial GMP-compliant continuous freeze-drying system, drying product "in hours, not days", scalable from R&D to 2 million vials a year with limited revalidation.

What the record shows

A patented spin-freezing method, a laboratory unit used by Coriolis, Thermo Fisher and Astellas, lab-scale posters reporting cycles cut from days to hours, a peer-reviewed scale-out test on a GMP-compatible prototype, an industrial investor in IMA Life, research grants from the EU and the Gates Foundation, and filed accounts with €322,343 of 2025 sales, a €1.61M loss and 4.4 FTE.

Verdict

RheaVita has moved spin freezing from a university prototype into equipment that large drug makers are testing, and the managing director of its industrial investor IMA Life sits on its board. The EIC selection backs the step that the 2021 round was already meant to fund: a production line that a manufacturer buys and runs under GMP. Sources reviewed on 18 November 2026 name no such buyer, the published speed gains come from lab-scale posters and a prototype scale-out paper rather than a production installation, and sales in the filed accounts fell by more than half between 2024 and 2025. The project is the test of whether the laboratory interest turns into production orders.

The reporting is based on publicly available sources, listed below.

Sources

  1. EIC, The European Innovation Council selects 35 deep tech companies for its Accelerator support, 16 November 2026, with the list of selected companies
  2. Crossroads Bank for Enterprises (KBO), RheaVita, 0695.884.829
  3. Companyweb, RheaVita, filed accounts 2022 to 2025
  4. Busibee, RheaVita, directors, filed accounts 2018 to 2025 and Official Gazette publications
  5. RheaVita, About page
  6. RheaVita, Team page
  7. RheaVita, RheaLyo Mono
  8. RheaVita, RheaLyo GMP-Flex lines
  9. RheaVita, News
  10. RheaVita, Patheon brings RheaVita's technology to Monza site
  11. Google Patents, US 10,809,003 B2, Method and apparatus and container for freeze-drying
  12. The Medicine Maker, Taking lyophilization for a spin, 30 July 2024
  13. BioSpace, RheaVita closes EUR 2.5 million Series A financing, 2 June 2021
  14. IMA Group, IMA Life announces strategic partnership with RheaVita, 18 November 2024
  15. Drug Discovery Online, Coriolis Pharma and RheaVita join forces, 28 July 2023
  16. CPHI Online, From conventional batch lyophilizer to continuous spin freeze-drying technology, 29 July 2026
  17. CPHI Online, Astellas feasibility study for continuous freeze-drying, 29 July 2026
  18. Bioprocess Online, Controlled continuous lyophilization webinar, 9 September 2026
  19. Turdo et al., From conventional batch lyophilizer to continuous spin-freeze-drying technology, PDA Italy Chapter poster
  20. Yoshikata et al. (Astellas), Feasibility study for continuous freeze-drying, PBP World Meeting 2026
  21. Laleman et al. (Ghent University and GSK), Spin-freeze-drying of a live attenuated viral vaccine, CESPE 2023 poster
  22. RheaVita, References
  23. Schaal et al., From R&D to production: Scale-out of continuous spin-freeze-drying for a PEGylated peptide formulation, International Journal of Pharmaceutics 700 (2026) 127077
  24. CEPI, New spin freezing technique could enhance future mRNA vaccines, 11 March 2024
  25. Gates Foundation, committed grant INV-105572 to RheaVita BV
  26. CORDIS, BAXERNA 2.0, grant agreement 101080544
  27. European Commission, New pandemic preparedness facilities inaugurated under HERA's EUFab network, 3 February 2025

Industry

Industrial technologyProcess equipment

AlsoHealthLife science tools

Focus
  • Reactors and thermal equipment
  • Laboratory instruments
Technologies
  • Thermal processing
  • Bioprocessing
  • Industrial automation
Keywords
  • Freeze-drying
  • Pharmaceutical manufacturing
  • Continuous manufacturing
  • Vaccine production
  • RNA therapeutics